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Abstract 
Objectives: Ovarian cancer is often diagnosed at an advanced stage, and consequently high 
levels of distress are often experienced.  It is necessary to understand the factors associated 
with psychological distress in order to guide interventions to target those factors.  The 
purpose of this systematic review was therefore, to identify correlates of psychological 
distress in ovarian cancer.   
Method: Included studies had to be quantitative and empirical, with standardized measures 
of psychological distress (anxiety or depression), and to present results for ovarian cancer 
patients specifically. Standard systematic search methods were used. Information about 
design, ovarian cancer sample size, disease stage, time since diagnosis, measures of distress 
used and findings was extracted from each study. The studies were quality assessed using 
experimenter-defined criteria as good, average and poor quality. Strength of the evidence 
(strong, some, inconclusive) was based on the quality and consistency of findings.  
Results Eighteen studies meeting the inclusion criteria were identified. There was strong 
evidence for a relationship between younger age, being diagnosed with more advanced 
disease, more physical symptoms and shorter time since diagnosis with increased levels of 
anxiety and/or depression. Additional factors (e.g., immune) tested in few studies also 
emerged as correlates of distress.  
Conclusions Demographic, disease and quality of life factors correlated with distress. 
However, too few studies assessed possible psychological and immunological correlates, 
which could be potentially modified and should be assessed in future studies.  
Keywords: cancer, oncology, ovarian cancer, anxiety, depression 
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Ovarian cancer is usually diagnosed at an advanced stage and the overall 5-year 
survival rate is approximately 40% [1].  Treatment usually involves radical surgery and 
chemotherapy, which can have a significant impact on quality of life, and risk of recurrence 
is high [1].  Not surprisingly, a number of studies have found elevated levels of anxiety and 
depression in patients with ovarian cancer [2-4].  However, one longitudinal study [5] found 
that 23% of ovarian cancer patients experienced little or no distress.  Thus, the psychological 
sequelae of ovarian cancer is quite heterogeneous. Identifying systematic and reliable 
research-based risk factors of psychological distress/reduced quality of life could help to 
guide psychological support and/ or interventions to those who require them the most.   
     This is a significant issue.  A study of 143 women with ovarian cancer found that although 
55% of participants had experienced some depressive symptoms, very few had been offered 
counselling [3].  Further, a search of the literature from 1980 – 2005 revealed only five 
psychological intervention studies for patients with gynaecologic cancers [6-10].  To further 
this research, it is necessary to identify correlates of psychological distress.  This will allow 
us to improve screening for interventions, guide their therapeutic contents and improve their 
efficacy.  In order to identify such correlates, it is necessary to review the literature carefully, 
assessing articles for study quality.  The latter could vary widely and significantly affect the 
inferences that can be drawn.   
A review on quality of life in ovarian cancer [11] noted several methodological 
limitations.  First, the absence of a clear-cut definition of quality of life led to uncertainties in 
theoretical and operational concepts.  Second, very few studies controlled for disease stage 
and other prognostic factors.  Third, many studies modified valid versions of psychometric 
instruments.  Fourth, many studies used small samples with possible insufficient statistical 
power. Some studies included patients with a variety of cancers, without presenting results 
for ovarian cancer patients separately, making inferences about ovarian cancer nearly 
impossible. Since many different measures were used, it was not possible to do a meta-
analysis. Overall, only limited conclusions could be drawn.  Although many of these issues 
have been addressed in subsequent studies, others, such as the ratio of variables to 
participants, use of non-standardized questionnaires, and failure to report results by 
type of cancer are still prevalent.   
       However, during the past decade there has been a substantial increase in research 
assessing levels of psychological distress and factors affecting psychological adjustment in 
ovarian cancer.  Although Pearman [12] carried out a review on quality of life and 
 4 
psychosocial adjustment in gynaecologic cancer survivors, several issues limit the 
conclusions that can be drawn by this review.  First, no specific period for the literature 
search was provided.  Second, the only database searched was Medline.  Third, gynaecologic 
cancer patients were not differentiated, although factors that may affect psychological 
adjustment can differ considerably depending on diagnosis. For example, ovarian cancer 
generally has a worse prognosis than cervical and endometrial cancers, since it is more likely 
to be diagnosed at a later stage.  Furthermore, in recent years new articles on distress in 
ovarian cancer have been published.  Fourth, the strength of evidence could not be assessed, 
as studies were not quality assessed. 
     The purpose of this review was to assess correlates of psychological distress 
(conceptualized as levels of anxiety and depressive symptoms) in ovarian cancer.  This 
review covered the period from January 1994 (to include any articles missed by the previous 
review on quality of life in ovarian cancer) to May 2007.  The studies were quality assessed, 
and divided into good, average and poor quality, in order to assess the strength of evidence. 
 Method  
Four methods were used to locate relevant studies: a keyword search, a backward 
search, a manual search of relevant journals, and a manual conference program search.  
Using the keyword search method, we searched the databases Medline, PsycInfo and Embase 
for articles published in the English language covering the period from January 1994 to May 
2007, with the provision that any articles published in 1994 and included in the previous 
review [11] were not included.  The search included the following terms: ovarian cancer 
NOT genetic (because the review was concerned with women who already had ovarian 
cancer), ovarian carcinoma, gynaecologic cancer, gynecologic cancer, psych$, depression, 
major depression, anxiety, anxiety disorders, distress, and stress.  After each term had been 
entered into the keyword function, the cancer-related terms were combined using the OR 
function, and so were the psychological terms.  A further search was then conducted, 
whereby the results of the previous searches were combined using the AND function.  This 
generated 798 hits.  Overall, the keyword search yielded 49 articles.   
     Following the keyword search, we carried out a backward search, in which we located 
papers by examining the reference lists of all papers obtained from the first step (as well as a 
recent non-systematic literature review; Pearman, 2003).  This did not identify any further 
articles. 
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     We then carried out a manual search of the journals Gynecologic Oncology (from which 
we had identified a number of articles) and Psycho-Oncology for the period January 1994 – 
May 2007.  This did not identify further articles. 
     Following this, we contacted the authors of unpublished dissertations, to enquire whether 
they had written any relevant articles based on their dissertation.  This method identified a 
further two manuscripts.   
     We also examined the abstracts of the 2006 World Congress of Psycho-Oncology.  This 
identified a further 3 studies. Overall, 49 published studies and 5 unpublished studies were 
identified. 
     Following this, we e-mailed the authors of the unpublished studies to request manuscripts.  
One author was not contactable at the email address provided.  A further two authors did not 
respond with sufficient information to enable inclusion of their studies in this review.  
Therefore, only 2 unpublished studies were obtained. 
 
Inclusion and exclusion criteria 
 
To be included, studies had to meet the following criteria:  
1) Either include ovarian cancer patients only, or to present the results for ovarian cancer 
patients separately.  Twenty-one studies were excluded according to this criterion, 
either because they were concerned only with patients with cervical and endometrial 
cancer (3 studies), or because ovarian cancer results were not presented separately (18 
studies).   
2) Be a quantitative study with standardized or validated measures of psychological 
distress.  Nine studies with qualitative methods were excluded. 
3) Present new data not already reported in an earlier source.  Three articles were 
excluded according to this criterion. 
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    Extracted information  
The following information was extracted from each study: report information 
(authors, year of study, source of study), ovarian cancer sample size, age of participants, 
disease stage at diagnosis, time since diagnosis, measures used (including whether they were 
standardized), design and major findings.  
Ratings of study quality 
     A methodological quality assessment list was used to assess the studies.  This was devised 
based on reviewing existing quality assessment lists, [13,14] extracting those criteria that 
were considered relevant, and devising further ones based on consultation, to cover all 
sections of the articles.  Since quality assessment was generic, the criteria could be applied to 
a variety of different types of study design.  These criteria are summarized and elaborated on 
in Table 1.  To reduce subjectivity in ratings, most criteria (10/12) could be assessed 
objectively with little interpretation. Each criterion was assessed out of 3 points (poor, 
medium and good).  Appendix 1 provides a full account of the quality assessment tool. 
Overall assessment 
     The studies are summarized in Table 2 together with their findings. They were assessed 
out of 36 points.  Studies that scored 30 points or above (> 80%) were classified as good, 
those that scored 26-29 points were classified as average, and those scoring 25 points or 
lower were classified as poor.   
     When collating the findings, the strength of evidence for a relationship between 
demographic and other factors and psychological adjustment was assessed by defining three 
levels of evidence.  Levels of evidence were based on those set out by Ariens et al. [13], and 
related to both quantity and quality, and are as follows: 1. Strong evidence: Consistent 
findings across two or more good studies; 2. Some evidence: Consistent findings across two 
or more studies, where at least 1 must be average; 3. Inconclusive evidence: Consistent 
findings in multiple poor studies, inconsistent findings, or only one study is available, 
irrespective of quality. 
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Results 
Eighteen studies were identified in this systematic review.  The majority were 
carried out in the USA (11 studies).  Other studies were carried out in Australia (3 
studies), Canada (1 study), Hong Kong (2 studies), and the UK (1 study).  Thirteen of 
the studies dealt with ovarian cancer patients only (2 of those studies focused on 
survivors), and 5 dealt with women with a variety of gynaecologic cancers including 
ovarian cancer, for which the pertinent results could be interpreted. 
The quality assessment highlighted a number of limitations with the studies.  
First, psychological studies were less likely to report biomedical variables, such as 
type of treatment, and medical studies were less likely to report other demographic 
variables, such as socioeconomic status (SES), and marital status.  Second, some 
studies that compared the prevalence of anxiety and depression in ovarian cancer 
patients to the general population did not have a control group. Third, there were a 
few issues with the statistical tests - dividing data into quartiles to address the issue of 
skew, rather than transforming variables (1 study) and doing Pearson correlations 
only, rather than regression (2 studies). Fourth, means and standard deviations were 
not always reported.  Fifth, many studies had rather small samples – eight failed to 
meet the criterion of 10 participants per independent variable required for 3 points.  
Finally, some of the studies used non-standardized assessment tools (that had not been 
validated and published) to assess secondary outcomes.     Table 1 provides the major 
limitations of each study. 
Overall, twelve of the studies were rated as methodologically good, five were 
rated average, and one was rated poor.  Levels of depression in ovarian cancer groups 
tended to be higher than in community samples, with percentages of those scoring 
above the clinical cut-off ranging from 21-25% in the good studies, to 33% in the 
poor study [5] (though, interestingly, this study found that 23% of individuals 
experienced little or no distress).  Notably, the prevalence of depression decreased 
after the three month period following completion of treatment [21], although it does 
not appear to differ across the first 6 weeks post-diagnosis [27]. However, it is 
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important to note that studies involving patients who were at varying stages of their 
cancer journey found approximately that approximately 25% of participants scored 
above the clinical cut-off, suggesting that depressive symptoms may remain a 
significant problem for some patients.  Studies that looked at ovarian cancer survivors 
found that 6% of ovarian cancer survivors, defined as those who had been 2 years or 
more without evidence of active disease, scored above the clinical cut-off for 
depression [29], which is comparable to the general population and survivors scored 
higher on the Mental Health Inventory than population norms, indicating better 
mental health than the general population [28].  Overall, levels of anxiety tended to be 
higher than levels of depressive symptoms [3].  Hipkins et al. [21] reported that the 
prevalence of clinical levels of anxiety was 47% 3 months after finishing treatment, 
and that anxiety increased from completion of treatment to 3 month follow-up.  
Correlates of levels of anxiety and depressive symptoms are reported in Table 3. 
 
     One factor constantly associated with increased levels of distress in ovarian cancer 
patients included younger age, where evidence was found in five good studies 
[3,4,15,16,26] and one average study [21].  In contrast, 1 average study [28] found no 
relationship between age and depressive symptoms in ovarian cancer survivors, and 
one good study [25] found lower levels of distress in women under 45 years old.  The 
weight of the evidence therefore strongly suggests that younger patients experience 
more anxiety/depression.  
     Being diagnosed with advanced stage disease was associated with increased levels 
of psychological distress in three good studies [3,16,25] and one poor study [5], 
although two average studies found no relationship between disease stage and levels 
of distress (Hipkins et al., 2004; Stewart et. al, 2001 – ovarian cancer survivors).  
Based on these results, there is strong evidence that having advanced stage disease at 
diagnosis is associated with higher levels of psychological distress.  Shorter time since 
diagnosis was associated with increased levels of distress in three good studies 
[3,17,22], although it is important to note that this was not assessed in a large number 
of studies, since participants were often recruited when they were newly diagnosed.  
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     Worse performance status was associated with increased levels of psychological 
distress in one good study [15] and one poor study [5], although one average study 
[21], found no relationship between Karnofsky performance status and levels of 
depression/anxiety.  This suggests inconclusive evidence for a relationship between 
Karnofsky performance status and levels of psychological distress.   
     Increased levels of physical impairment was related to increased levels of 
psychological distress in two good studies [4,22] and one poor study [5]. Related to 
this, 1 average study on ovarian cancer survivors [29] found that increased levels of 
self-reported neurotoxicity was associated with increased levels of depression. From 
these findings, it was concluded that there is strong evidence for a relationship 
between increased levels of physical symptoms and increased levels of psychological 
distress.  Phase of treatment (active/ follow-up) was not associated with levels of 
depression/anxiety, in the one good study that addressed this issue [16].  Also no 
differences in psychological distress were found between those with newly diagnosed 
and recurrent cancer in one average study [20], suggesting that both cancer phases are 
psychologically equally difficult.  
     Regarding cancer site, three studies assessed several different types of 
gynaecologic cancers.  Two good studies [16,17] and one average study [27] found no 
differences between patients with ovarian cancer and those with other types of 
gynaecologic cancers.  However, one good study [25] found that women with ovarian 
cancer experienced lower levels of depressive symptoms than those with cervical and 
endometrial cancer.  This study included very few participants with advanced stage 
disease, which may account for this difference.  These results do not suggest any clear 
relation between cancer site and levels of psychological distress. 
     Poor perceived social support was associated with increased levels of anxiety and 
depression in one good study [4] and two average studies [21,27].   This was assessed 
in different ways across the studies i.e. perceived social support [27], perceived 
emotional support [21], and perceived unsupportive family/friend behaviours [4], 
which adds to the robustness of the evidence.  These findings suggest moderate 
evidence for a relationship between perceived social support and levels of 
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psychological distress.  Also, depression at time of diagnosis was a significant 
predictor of depressive symptoms 3 months later, and levels of anxiety and intrusive 
thoughts at time of diagnosis were significant predictors of levels of anxiety 3 months 
later in one average study [21].  
 Increased levels of distress were associated with worse quality of life in two 
good studies [22,25].  However, these results should be viewed with caution, because 
although Molassiotis et al. [25] found that depression accounted for 45% of the 
variance in quality of life, the scale used contained mood items. 
     Finally, some interesting issues were assessed in single studies.  The relationship 
between levels of distress and immune factors was assessed in three good studies 
[18,23,24].  Costanzo et al., [18] found that a history of depression and increased 
depressed mood were associated with higher levels of interleukin-6 in ascitic fluid.  
Lutgendorf et al. [23], found that higher levels of helplessness were associated with 
higher levels of vascular endothelial growth factor, a pro-angiogenic factor which is 
associated with poorer survival.  Lutgendorf et al. [24], found increased levels of 
distress were associated with lower levels of natural killer cells in tumour-infiltrating 
lymphocytes. Thus, various indices of distress are correlated with biomarkers of 
important prognostic factors in ovarian cancer.  Parker et al. [26], in a good study, 
found that lower levels of knowledge about ovarian cancer and higher CA 125 levels 
were associated with increased levels of depressive symptoms. Furthermore, the 
latter association was moderated by knowledge levels, such that it did not occur if 
knowledge about ovarian cancer was low, suggesting that depth of understanding of 
the illness links CA125 with depression. Increased anxiety was associated with lower 
levels of knowledge about ovarian cancer, and with higher levels of preoccupation 
with CA 125.  de Moor et al. (2006), in a longitudinal study, found that CA 125 
positively correlated with anxiety and depression at baseline, but no prospective 
relations were found.  Boscaglia et al. [16], in a good study, found that increased 
levels of negative religious coping (i.e., confusion and dissatisfaction with God, 
redefining the illness as a punishment) were associated with higher levels of anxiety 
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and depression.  The results from these studies point at possible complex relations 
between information-seeking, coping and distress in ovarian cancer. 
 
Discussion  
     In order to identify correlates of psychological distress in ovarian cancer, a 
systematic review of the literature was carried out.  The results showed strong 
evidence for a relationship between younger age, being diagnosed with more 
advanced disease, more physical symptoms and shorter time since diagnosis with 
increased levels of anxiety and depression; some evidence for a relationship between 
low perceived social support and worse performance status and increased levels of 
anxiety/depression was also found. There was inconclusive evidence for a relationship 
between being on active chemotherapy, having a recurrence and having ovarian 
cancer (compared to other gynaecologic cancers) and levels of anxiety/depression. 
While the evidence for a relationship between quality of life and distress could be 
viewed as strong based on our criteria, the issue of item overlap (quality of life 
instruments often include measures of mood) spuriously inflated this relationship.  
     Overall, a consistent relationship was found between younger age and increased 
levels of anxiety/ depression.  Similar findings have been reported in other cancers 
i.e., Strong et al. [30].  Individuals diagnosed at a younger age have several issues to 
contend with, including the impact of their diagnosis on those around them (e.g., 
spouses, children), issues about childbearing, multiple unfulfilled goals, and the 
possibility of an early death.  Although younger women are more likely to be married 
(than widowed), and possibly have a wider social network, the disease is more likely 
to impact on their everyday life.  The evidence presented here suggests that younger 
women should be carefully assessed for symptoms of anxiety and depression. 
     Physical symptoms and impairment were also associated with increased levels of 
anxiety and depression, possibly because they are viewed as indicators of disease 
progression. In addition, some treatment-induced physical symptoms (e.g., nausea) 
may either induce or be associated with altered mood state as part of the “sickness 
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response” [31].  Similarly, lower performance status was associated with increased 
levels of anxiety/ depression.  This evidence suggests that individuals with limited 
ability to perform daily activities may benefit from psychological interventions, and 
that psychological interventions should be tailored to accommodate their limitations 
(i.e., by phone for people who are unable to travel).  Alternatively, depression or 
anxiety may lead to poorer performance status because depressed patients have 
reduced motivation [32] leading to reductions in energy expenditure required for daily 
activities. It is also plausible that relations between self-reported physical symptoms 
and distress may reflect the underlying personality trait of neuroticism [33], 
manifested by corresponding scores on both outcomes.  Objective measures of 
physical health or statistically controlling for neuroticism may be required to test the 
true relation between impairment and distress.   
     More advanced disease was associated with increased levels of distress in newly 
diagnosed patients. Advanced stage disease is associated with poorer survival and 
more symptoms, and patients are obviously aware of these threats. This evidence 
suggests that individuals diagnosed with advanced disease should be carefully 
assessed for anxiety and depression. 
 As in other cancers [34], levels of anxiety/ depression tended to decrease as 
time since diagnosis increased.  A cancer diagnosis is a traumatic event, and coming 
to terms with it requires a significant shift in perspective, which could explain these 
findings. This may reflect an adaptation process. 
 As expected, poorer quality of life was significantly associated with increased 
levels of anxiety/ depression.  Experiencing more physical symptoms and reduced 
ability to engage in leisure activities/ work is likely to decrease self-esteem, possibly 
leading to greater distress. Future studies need to test whether self-esteem mediates 
such a relation. This evidence suggests that interventions targeting quality of life are a 
high priority area for future research, and should be made widely available, 
particularly given the relations between quality of life and distress/ survival [35, 36]. 
However, as mentioned above, these relations may partly stem from item overlap and 
need to be tested by removing distress items from quality of life instruments.  
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 As expected, given previous studies on other types of cancer, i.e., Helgeson & 
Cohen, [37] poor perceived social support was associated with increased levels of 
anxiety and depression.  This may result from patients not receiving sufficient 
emotional or instrumental support from close friends/ relatives. Alternatively, high 
patient distress may lead to reduced social support due to significant others not having 
the skills to manage such distress. 
     The evidence assessed here suggests no differences in levels of anxiety and 
depression between patients with ovarian cancer and those with other gynaecologic 
cancers.  Similar findings were observed in two excluded studies [38, 39].  Ovarian 
cancer has a worse prognosis as it is more likely to be diagnosed at an advanced stage, 
and consequently requires more aggressive treatment, both of which are distressing.  
However, provided disease stage was controlled for in these studies, this lack of 
difference is expected since cancer can be life threatening and all gynaecologic 
cancers may affect sexual relations and intimacy.  Thus, other factors related to the 
disease mentioned above, rather than the mere diagnosis of ovarian cancer, should be 
considered when assessing anxiety and depression [5]. 
     Being on active chemotherapy treatment was not associated with increased risk of 
anxiety and depression.  This was surprising since chemotherapy can cause a number 
of unpleasant side effects, often greatly reducing life satisfaction and inducing the 
sickness response. A number of the studies here included only newly diagnosed 
individuals. However, patients undergoing chemotherapy are aware that their 
condition is being treated, which may reflect an important source of medical support. 
Upon completion of treatment, some patients experience anxiety that their progress is 
not being monitored, and that they will be unaware of a recurrence (particularly since 
ovarian cancer can be asymptomatic). Similar “separation anxiety” is found in 
patients leaving the intensive coronary care unit for less intensive monitoring and care 
in other parts of hospitals [40]. Also surprisingly, having a recurrence was not 
associated with increased levels of anxiety and depression.  In these studies, 
individuals who had a recurrence were compared with newly diagnosed patients.  
Comparing patients who had a recurrence with disease-free individuals at a similar 
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time since diagnosis may yield different results.  Alternatively, this result could be 
explained in the following way: by the time of recurrence, some individuals have been 
living with their illness for several years, and may have come to terms with their 
diagnosis and treatment – news of a recurrence may be less surprising than the initial 
diagnosis.  This issue requires further research.  
    A few well-designed studies found that various indices of distress were correlated 
with biomarkers of prognostic factors in ovarian cancer (e.g., VEGF, IL-6).  Since 
distress may lead to altered immune function, interventions to reduce distress need to 
be made a priority. These studies are important since they point at potential mediators 
linking psychological factors with prognosis in ovarian cancer e.g.[41]. However, this 
needs to be tested in longitudinal studies and randomized controlled trials, which 
would provide a better understanding of the direction of the relation between immune 
factors and psychological distress.   
    Regarding methodology/ reporting, several issues need to be addressed in future 
studies.  First, information should be collected on whether the individual is living 
alone or with a partner, socioeconomic status, type of treatment received and whether 
the patient has had a recurrence.  Second, more prospective studies and randomized-
controlled trials are needed, the latter enabling causal inferences and having potential 
clinical value.  In addition, longitudinal studies should test trajectories of change in 
distress following diagnosis and treatment.  Third, more attention should be given to 
sample size. Fourth, questionnaires should be validated prior to usage if possible.  
Fifth, importantly, studies should use models to structure their research questions – to 
date, most studies have not been based on theory regarding adjustment to illness [42, 
43].  Finally, limitations and possible future directions for research should be 
provided.  Although some of these conclusions echo those of Montazeri et al. [11], 
which would suggest lack of progress in recent years, the studies published in the 
current decade were rated  ‘average’ or better, in contrast with the study published in 
the 1990s.  It is also encouraging to see that the volume of published research on 
ovarian cancer has been increasing in recent years – over half the studies included in 
this review were published after 2003.  In addition, the studies revealing relationships 
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between distress and disease biomarkers indicate promising avenues and call for 
testing whether treating distress could alter such biomarkers and improve prognosis in 
ovarian cancer.  Also, some studies point to a number of modifiable factors affecting 
levels of distress, such as levels of knowledge and coping strategies, which were not 
assessed in the ovarian cancer literature before the late 1990s. Given recent reviews 
on psychological interventions and prognosis in cancer [44], future studies need to 
design alternative interventions for modifying psychosocial factors. 
This systematic review had a few limitations. A number of authors were 
reluctant to provide details of unpublished studies, which consequently could not be 
included. Some correlates of distress (e.g., immune factors, coping) were tested in too 
few studies to enable firm conclusions. 
Overall, this review has provided a first step towards identifying factors that 
may impact on psychological distress in ovarian cancer, a disease that has often been 
neglected in psycho-oncology research until recently. This is also the first review to 
quality assess studies, and therefore provides a more stringent test of the evidence 
than previous reviews on ovarian cancer.  The evidence here can be used as a 
preliminary guide when deciding which patients to assess for anxiety and depression 
and whom to target when designing psychological interventions.   
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Table 1: Criteria for Quality Assessment 
   Item definition 
Rationale Was there sufficient theoretical background to justify the study aims? 
Disease 
variables 
Was time since diagnosis reported? 
 Was disease stage reported? 
 Were background biomedical and demographic variables reported? 
Study 
design 
Was the study cross-sectional/ case-control, prospective or a RCT? 
 Was the choice of design adequate for the research question 
Analysis 
and data 
presentation 
Were adequate statistical tests carried out (of sufficient complexity)? Were 
important biomedical & demographic variables considered? 
 Were the descriptive and inferential statistics presented adequately? 
 Was the sample size sufficient in relation to the number of independent 
variables (at least 10 times the number of IVs in the analysis)? 
Measures 
used 
Were reliable and valid measures used to assess psychological distress? 
Discussion Were the conclusions justified based on the design and research findings? 
 Were the limitations reported? 
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Table 2: Prevalence and correlates of distress, and quality assessment of studies  
Ref 
no. 
Article 
reference 
Design Ovarian 
cancer  
(N) 
Disease 
stage (I – 
IV) 
Time since 
diagnosis 
(months) 
Measures of 
distress 
used 
Findings Quality Assessment 
score (12-36) and major 
limitations 
1 [15] (Bodurka 
Bevers et al., 
2000) 
 
CR 246 181 – III/ IV  
65 – I/II 
0.3-364 
(median 28.5) 
CES-D; 
STAI – state 
anxiety  
1) 21% had probable clinical depression 
2) Poor performance status a/w high depression, anxiety, low 
QoL 
3) Younger age related to greater likelihood of depression  
30  
disease stage/ time since 
diagnosis, study design, 
limitations 
2 [16] 
(Boscaglia et 
al., 2005) 
 
CR 100 60 – I;  
11 – II;  
28 – III; 
1 – IV 
Under 1 year 
(mean 22.21 
weeks, SD = 
14.58) 
BDI for 
Primary 
Care; STAI 
– state 
anxiety;  
1) 24% at least mild symptoms of depression, mean anxiety 
higher than general population 
2) Younger age, advanced stage of disease, greater level of 
negative religious coping: a/w higher level of depression 
3) Negative spiritual coping correlated with higher anxiety 
4) Phase of treatment (active versus not active) and site of cancer 
(ovarian versus not ovarian) unrelated to depression or anxiety 
30  
sample size, data, 
demographics 
3 [17] (Chan et 
al., 2005) 
RCT 39 
interventi
on (T), 
36 control 
(C) 
88 – I;  
18 – II;  
40 –III;  
9 – IV 
 
Newly 
diagnosed 
BDI; Beck 
Anxiety 
Inventory;  
1) No effect of the intervention on any measure 
2) Lower educational level a/w less anxiety 
3) No significant differences between ovarian cancer and other 
gynaecologic cancers in levels of anxiety and depression 
 
31  
introduction, data, 
sample size, limitations 
4 [18] (Costanzo 
et al., 2005) 
 
CR 61 45 - III,  
16 –IV 
Newly 
diagnosed  
POMS-SF; 
CES-D;  
1) Elevated levels of distress in advanced-stage cancer compared 
to community samples 
2) History of depression a/w higher levels of IL-6 in ascitic fluid 
 
33 
demographics  
5 [19] (de Moor 
et al., 2006) 
LN 90 
(complete 
follow-up) 
8% - I,  
7% - II, 
66% - III, 
17% - IV 
Mean 2.60 
years (SD 
3.11) 
PSS; STAI; 
CES-D  
1) Optimism negatively a/w anxiety, stress and depression at 
baseline and follow-up 
2) CA 125 a/w anxiety at baseline but not follow-up 
 
35 
 
6 [20] (Donovan 
et al., 2002) 
CR 151 (81 
initial 
cancer, 70 
recurrent) 
77% -III/ IV Recently 
diagnosed/ 
being treated 
for a 
recurrence 
POMS-SF   1) No differences in POMS between those with newly diagnosed 
and recurrent cancer 
 
28 
intro, time since 
diagnosis, demographics, 
stats, sample size, 
limitations 
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7 [21] (Hipkins 
et al., 2004) 
 
LN 57 65% -III/ IV Mean 6.1 
months 
HADS  1) Anxiety at T1, perceived emotional support and younger age 
a/w anxiety at T2 
2) IES-intrusions at T1 a/w anxiety at T2  
3) Depression at T1 and perceived emotional support associated 
with depression at T2 
4) Increase in anxiety, decrease in depression over 3 months 
28 
demographics, data,  
questionnaire, limitations 
 
8 [22] 
(Hodgkinson 
et al., 2007) 
CR 54 (27%) 59% -  I, 
17% -  II, 
22.6% - III, 
1.5% - IV 
Mean 3.7 
years (SD 2.3) 
SF-12; 
HADS  
1) 5.5% cases of depression, 14% anxiety (higher than general 
population) 
2)Correlates of distress: poorer physical and mental QoL, PTSD, 
higher total needs 
3) Extended survival a/w lower anxiety 
31  
intro, time since 
diagnosis, limitations 
9 [5] (Kornblith 
et al., 1995) 
LN 151 at 
start 
86%  III/IV Not reported MHI  1) In 1/3 of patients, symptoms of anxiety and depression 
occurred at levels of moderate to very severe intensity 
2) 33% had high levels of psychological distress 
3) High distress a/w more physical symptoms, worse physical 
functioning, worse current well-being, advanced disease, being 
an inpatient on study entry 
4) Physical symptoms, physical functioning and performance 
status -predictors of psychological distress 
5) 23% - little or no distress 
25  
intro, time since 
diagnosis, disease stage, 
demographics, stats, data, 
sample, questionnaires, 
limitations 
10 [23] 
(Lutgendorf et 
al., 2002) 
 
CR 24 19 III/IV New diagnosis 
(before 
surgery) 
POMS  1) Higher levels of helplessness a/w higher VEGF 31  
sample size, data 
11 [24] 
(Lutgendorf et 
al., 2005) 
 
CR 42 83% III/ IV Newly 
diagnosed 
(after surgery) 
POMS (SF) 1) No significant differences in distress, depressed mood 
between groups 
2) More distress associated with poorer NKCC in TIL 
33  
sample size 
12 [25] 
(Molassiotis et 
al., 2000) 
 
CR 35 
(56.5%) 
3- borderline 
21 – I, 
19 –II,  
3 –III,  
1 – IV 
52.3 months 
(SD 45.1, 
range 6 
months – 13 
years) 
POMS  1) Lower levels of mood disturbance, lower levels of depression 
in ovarian than cervical cancer 
2) Younger age, early stage disease a/w better psychological 
health 
4) Depression accounted for 45% of variance in QoL  
30  
intro, study design, 
sample size, 
questionnaire 
13 [3] (Norton et 
al., 2004) 
 
CR 143 39% - III Mean 22 mths 
(49% 
diagnosed 
within 6 mths) 
BDI (not 
somatic 
items); MHI  
1) Higher levels of depression than community samples 
2) Higher levels of anxiety than depressive symptoms 
3) Younger age, less time since diagnosis and more advanced 
disease stage a/w more psychological distress 
31  
design, questionnaire, 
limitations 
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14 [4] (Norton et 
al., 2005) 
 
CR 143 46% - III 18 months (SD  
2.3 years) 
MHI 1) Older age a/w less anxiety and depression, 
2) Higher levels of physical impairment a/w lower perceived 
control over the illness , which a/w greater psychological distress 
3) Higher levels of unsupportive behaviours from family/ friends 
a/w lower self-esteem, which a/w greater psychological distress 
33  
questionnaire 
15 [26] (Parker et 
al., 2006) 
 
CR 126 85% - III/IV Mean 2.7 
years (SD 3.4) 
CES-D; 
STAI;  
1) 25% scored above clinical cut-off 
2) Age negatively a/w depressive symptoms and anxiety 
3) CA125-preoccupation significantly a/w anxiety;  
4) Lower knowledge scores and higher CA125 preoccupation 
scores a/w more depressive symptoms - knowledge moderated 
association of CA125- preoccupation with depressive symptoms  
5) Anxiety negatively a/w knowledge, positively a/w CA125 
preoccupation 
31  
demographics, 
questionnaires, 
conclusions 
16 [27] (Petersen 
et al., 2005) 
 
LN 9 (35%) 61% - I, 
12% - II, 
27% - III  
Newly 
diagnosed 
Hopkins 
Symptom 
Checklist-
90;  
1) Levels of distress did not change over first 6 weeks 
2) No significant differences in levels of distress between 
ovarian cancer and other sites 
3) Distress a/w poor perceived social support 
26  
intro, disease stage, 
demographics, design, 
stats, data, sample, 
limitations 
17 [28] (Stewart 
et al., 2001) 
CR 200 Not reported 7.2 years (SD 
= 4.9) 
MHI 1) Mental health not affected by age, education, time since 
diagnosis 
26  
intro, disease stage, stats, 
data, questionnaires, 
limitations 
18 [29] (Wenzel 
et al., 2002) 
 
CR 49 38 – I;  
11 – II 
5 years or 
more (5-10) 
SF-36; CES-
D;  
1) Neurotoxicity a/w psychological well-being, depression 26  
demographics, stats, data, 
sample, questionnaires, 
conclusions, limitations 
 
Glossary: CR –cross-sectional; LN – longitudinal; RCT – randomized controlled trial; CES-D – Center for Epidemiologic Studies – Depression 
Scale; STAI – State Trait Anxiety Inventory; BDI – Beck Depression Inventory; POMS – Profile of Mood States; HADS – Hospital Anxiety and 
Depression Scale; MHI – Mental Health Inventory;  
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Table 3: Factors correlated with levels of anxiety and depressive symptoms in ovarian cancer 
 
Factor  Most 
frequently 
observed 
association  
Congruent 
with 
observations 
No 
relation 
Incongruent 
with 
observations 
Level of 
evidence 
Age Younger  – more 
distress 
 
Good: 5 
Average: 1 
Average: 1 
(survivors) 
Good:1 Strong 
Disease stage More advanced – 
more distress 
Good: 3  
Poor: 1  
Average: 2 
(1 on 
survivors) 
 
 Strong 
Time since 
diagnosis 
Shorter – more 
distress 
Good: 3 Good: 1 
Average: 1 
(survivors) 
 
 Strong 
Disability status Worse – more 
distress 
Good: 1  
Poor: 1 
 
Average: 1   Some 
Physical 
symptoms 
More symptoms 
– more distress 
Good:2 
Poor: 1 
 
  Strong 
Active 
chemotherapy/ 
follow-up 
 
Chemotherapy – 
more distress 
 Good:1  Inconclusive 
Phase of 
treatment: 
initial/ recurrent 
 
Recurrent – 
more distress 
 Average: 1  Inconclusive 
Site of cancer 
 
 
Ovarian – more 
distress 
 Good:1 
Average: 1 
Good: 1 Inconclusive 
Perceived social 
support 
More social 
support – less 
distress 
 
Good:1 
Average: 2 
  Some 
Previous levels of 
depression 
More – more 
distress 
 
Average: 1   Inconclusive 
Previous levels of 
anxiety 
More – more 
distress 
 
Average: 1   Inconclusive 
Previous levels of 
intrusive 
thoughts 
More  – more 
distress 
 
Average: 1   Inconclusive 
Quality of Life Poorer quality of 
life – more 
distress 
Good: 2   Strong 
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Appendix 1: Details of the quality assessment criteria 
Rationale 
Good: The introduction contained sufficient theoretical background to justify the study aims 
Medium: The introduction contained some theoretical background, but not all study aims 
were clear 
Poor: The introduction contained no theoretical background  
 
Time since diagnosis 
Good: All participants newly diagnosed, or time since diagnosis reported  
Medium: Time since diagnosis was not reported, but all participants were either newly 
diagnosed, or at the start of a new course of chemotherapy  
Poor: This information was not reported 
 
Disease Stage 
Good: This information was reported 
Poor: This information was not reported 
      
Background biomedical and demographic variables 
Good: Information was reported on whether the individual was living alone or with a partner, 
socioeconomic status, type of treatment received and whether the patient had had a 
recurrence.    
Medium: Information was not reported on one or more of these variables 
Poor: Information was not reported on any of these variables 
 
Study Design  
Good: Randomized controlled trial 
Medium: Prospective/ longitudinal study 
Poor: Cross-sectional study 
  
Suitability of the design to answering the research question:  
Good: Best possible design used 
Medium: Inappropriate control group used/ no control group when comparing levels of 
anxiety/ depressive symptoms to the general population 
Poor: Hypotheses suggesting causality tested in a cross-sectional design       
 
Were adequate statistical tests carried out? 
Good: The best statistical tests possible were used 
Medium: The statistical tests could have been better (i.e. data divided into quartiles to 
address the idea of skew, rather than transforming variables, doing Pearson correlations only, 
rather than regression) 
Poor:  Failure to use inferential statistics, or explain the statistical tests properly 
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Presentation of the statistical tests 
Good:   Means and standard deviations were fully reported, and the graphs were easy to 
understand 
Medium: Either means only were reported, or the graphs were not very clear 
Poor: Means and standard deviations were not reported.   
  
Sample size 
Good: More than 10 participants per independent variable 
Medium: The sample was adequately powered to assess single variables, but the number of 
participants per independent variable was less than 10 
Poor: A very small sample (under 30 participants)  
 
Measures Used 
Good: All the questionnaires used were standardized, defined as questionnaires that had been 
validated and published  
Medium: Some of the questionnaires (that assessed secondary outcomes) had not been 
standardized 
Poor: Reliability and validity information were not reported  
 
Were the conclusions justified based on the research findings? 
 
Good: All conclusions followed on logically from the research findings 
Medium: Not all conclusions were supported by the research findings 
Poor: Inferences of causality were made based on cross-sectional data 
 
Limitations 
Good: All limitations were mentioned 
Medium: The authors mentioned some limitations, but failed to point out others that the 
reviewers noticed 
Poor: No limitations of the study/ issues for future research were mentioned 
      
 
 
